Evaluation of verteporfin pharmakokinetics – redefining the need of photosensitizers in ophthalmology

Bibliography

• Brown DM, Michels M, Kaiser PK, ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: two-year results of the ANCHOR study. Ophthalmology 2009;116(1):57-65. e5
   PubMed Web of Science ®Google Scholar
• Bakri SJ, Kaiser PK. verteporfin ocular photodynamic therapy. Expert Opin Pharmacother 2004;5(1):195-203
   PubMed Web of Science ®Google Scholar
• Bressler NM, Chang TS, Fine JT, Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR) Research Group. Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. Arch Ophthalmol 2009;127(1):13-21
   PubMedGoogle Scholar
• Oner A, Karakucuk S, Mirza E, Erkilic K. Electrooculography after photodynamic therapy. Doc Ophthalmol 2005;111(2):83-6
   PubMedGoogle Scholar
• Tzekov R, Lin T, Zhang KM, Ocular changes after photodynamic therapy. Invest Ophthalmol Vis Sci 2006;47(1):377-85
   PubMedGoogle Scholar
• Ozdemir H, Karacorlu SA, Karacorlu M. Early optical coherence tomography changes after photodynamic therapy in patients with age-related macular degeneration. Am J Ophthalmol 2006;141(3):574-6
   PubMedGoogle Scholar
• Matsubara A, Nakazawa T, Husain D, Investigating the effect of ciliary body photodynamic therapy in a glaucoma mouse model. Invest Ophthalmol Vis Sci 2006;47(6):2498-507
   PubMedGoogle Scholar
• You IC, Im SK, Lee SH, Yoon KC. Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. Cornea 2011;30(1):30-3
   PubMedGoogle Scholar
• Moshfeghi DM, Peyman GA, Moshfeghi AA, Ocular vascular thrombosis following tin ethyl etiopurpurin (SnET2) photodynamic therapy: time dependencies. Ophthalmic Surg Lasers 1998;29(8):663-8
   PubMedGoogle Scholar
• Renno RZ, Delori FC, Holzer RA, Photodynamic therapy using Lu-Tex induces apoptosis in vitro, and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Invest Ophthalmol Vis Sci 2000;41(12):3963-71
   PubMedGoogle Scholar
• Criswell MH, Ciulla TA, Lowseth LA, Anastomotic vessels remain viable after photodynamic therapy in primate models of choroidal neovascularization. Invest Ophthalmol Vis Sci 2005;46(6):2168-74
   PubMedGoogle Scholar
• Obana A, Gohto Y, Kaneda K, PDT to monkey CNV with ATX-S10(Na): inappropriateness of early laser irradiation for selective occlusion. Invest Ophthalmol Vis Sci 2001;42(11):2639-45
   PubMedGoogle Scholar
• Ciulla TA, Criswell MH, Snyder WJ, Small W IV. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide, achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Br J Ophthalmol 2005;89(1):113-19
   PubMedGoogle Scholar
• Berdugo M, Bejjani RA, Valamanesh F, Evaluation of the new photosensitizer Stakel (WST-11) for photodynamic choroidal vessel occlusion in rabbit and rat eyes. Invest Ophthalmol Vis Sci 2008;49(4):1633-44
   PubMed Web of Science ®Google Scholar
• Bullous AJ, Alonso CM, Boyle RW. Photosensitiser-antibody conjugates for photodynamic therapy. Photochem Photobiol Sci 2011;10(5):721-50
   PubMedGoogle Scholar
• Miller JW. Higher irradiance and photodynamic therapy for age-related macular degeneration (an AOS thesis). Trans Am Ophthalmol Soc 2008;106:357-82
   PubMedGoogle Scholar
• Allison RR, Downie GH, Cuenca R, Photodiag Photodynam Ther. 2004;1:27-42
   Google Scholar
• Detty MR, Gibson SL, Wagner SJ. Current clinical and preclinical photosensitizers for use in photodynamic therapy. J Med Chem 2004;47:3897-915
   PubMed Web of Science ®Google Scholar
• Jesionek A, von Tappenier H. Zur Behandlung der Hautcarcinome mit mit fluorescierenden Stoffen. Muench Med Wochenschr 1903;47:2042
   Google Scholar
• Richter AM, Waterfield E, Jain AK, In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol 1990;52:495-500
   PubMed Web of Science ®Google Scholar
• Karsten AE, Singh A, Braun MW. Experimental verification and validation of a computer model for light-tissue interaction. Lasers Med Sci 2012;27(1):79-86
   PubMedGoogle Scholar
• Wilson BC, Patterson MS. The physics, biophysics and technology of photodynamic therapy. Phys Med Biol 2008;53(9):R61-109
   PubMed Web of Science ®Google Scholar
• Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers Med Sci 2002;17(3):173-86
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T. Mechanisms of action of photodynamic therapy with verteporfin for the treatment of age-related macular degeneration. Surv Ophthalmol 2000;45:195-214
   PubMed Web of Science ®Google Scholar
• Ansari-Shahrezaei S, Ergun E, Chong R, Magnification-corrected photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2007;245(3):333-7
   PubMedGoogle Scholar
• Ansari-Shahrezaei S, Binder S, Stur M. The effect of laser unit on photodynamic therapy spot size. Graefes Arch Clin Exp Ophthalmol 2011;249(1):11-14
   PubMedGoogle Scholar
• Ayaru L, Wittmann J, Macrobert AJ, Photodynamic therapy using verteporfin photosensitization in the pancreas and surrounding tissues in the Syrian golden hamster. Pancreatology 2007;7(1):20-7
   PubMedGoogle Scholar
• Barnes LD, Giuliano EA, Ota J. Cellular localization of Visudyne as a function of time after local injection in an in vivo model of squamous cell carcinoma: an investigation into tumor cell death. Vet Ophthalmol 2010;13(3):158-65
   PubMedGoogle Scholar
• Richter AM, Kelly B, Chow J, Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst 1987;79(6):1327-32
   PubMedGoogle Scholar
• Rousset N, Vonarx V, El´eouet S, Cellular distribution and phototoxicity of benzoporphyrin derivative and Photofrin. Res Exp Med (Berl) 2000;199(6):341-57
   PubMedGoogle Scholar
• Donohue E, Tovey A, Vogl AW, Inhibition of autophagosome formation by the benzoporphyrin derivative verteporfin. J Biol Chem 2011;286(9):7290-300
   PubMed Web of Science ®Google Scholar
• Krammer B.. Vascular effects of photodynamic therapy. Anticancer Res 2001;21(6B):4271
   PubMed Web of Science ®Google Scholar
• Chen B, Pogue BW, Hoopes PJ, Hasan T. Combining vascular and cellular targeting regimens enhances the efficacy of photodynamic therapy. Int J Radiat Oncol Biol Phys 2005;61(4):1216-26
   PubMedGoogle Scholar
• Schnurrbusch UE, Welt K, Horn LC, Histological findings of surgically excised choroidal neovascular membranes after photodynamic therapy. Br J Ophthalmol 2001;85(9):1086-91
   PubMedGoogle Scholar
• Schmidt-Erfurth U, Laqua H, Schlotzer-Schrehard U, Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol 2002;120(6):835-44
   PubMedGoogle Scholar
• Moshfeghi DM, Kaiser PK, Grossniklaus HE, Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophthalmol 2003;135(3):343-50
   PubMedGoogle Scholar
• Schmidt-Erfurth U, Niemeyer M, Geitzenauer W, Michels S. Time course and morphology of vascular effects associated with photodynamic therapy. Ophthalmology 2005;112(12):2061-9
   PubMedGoogle Scholar
• Fingar VH, Kik PK, Haydon PS, Analysis of acute vascular damage after photodynamic therapy using benzoporphyrin derivative (BPD). Br J Cancer 1999;79(11-12):1702-8
   PubMedGoogle Scholar
• He C, Agharkar P, Chen B. Intravital microscopic analysis of vascular perfusion and macromolecule extravasation after photodynamic vascular targeting therapy. Pharm Res 2008;25(8):1873-80
   PubMedGoogle Scholar
• Debefve E, Mithieux F, Perentes JY, Leukocyte-endothelial cell interaction is necessary for photodynamic therapy induced vascular permeabilization. Lasers Surg Med 2011;43(7):696-704
   PubMedGoogle Scholar
• Maar N, Pemp B, Kircher K, Ocular haemodynamic changes after single treatment with photodynamic therapy assessed with non-invasive techniques. Acta Ophthalmol 2009;87(6):631-7
   PubMedGoogle Scholar
• Tsuchihashi T, Mori K, Peyman G, Photodynamic effects on retinal oxygen saturation, blood flow, and electrophysiological function in patients with neovascular age-related macular degeneration. Retina 2009;29(10):1450-6
   PubMed Web of Science ®Google Scholar
• Petermeier K, Tatar O, Inhoffen W, Grisanti S. verteporfin photodynamic therapy induced apoptosis in choroidal neovascular membranes. Br J Ophthalmol 2006;90(8):1034-9
   PubMed Web of Science ®Google Scholar
• Matsubara A, Nakazawa T, Noda K, Photodynamic therapy induces caspase-dependent apoptosis in rat CNV model. Invest Ophthalmol Vis Sci 2007;48(10):4741-7
   PubMed Web of Science ®Google Scholar
• Houle J, Strong A. Clinical pharmacokinetics of verteporfin. J Clin Pharmacol 2002;42:547-57
   PubMed Web of Science ®Google Scholar
• Richter AM, Kelly B, Chow J, Preliminary studies on a more effective phototoxic agent than hematoporphyrin. J Natl Cancer Inst 1987;79(6):1327-32
   PubMedGoogle Scholar
• Richter AM, Cerruti-Sola S, Sternberg ED, Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice. J Photochem Photobiol B 1990;5(2):231-44
   PubMed Web of Science ®Google Scholar
• Richter AM, Waterfield E, Jain AK, Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumour tissue in a mouse tumour model. Photochem Photobiol 1993;57:1000-6
   PubMed Web of Science ®Google Scholar
• Richter AM, Waterfield E, Jain AK, Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer 1991;63:87-93
   PubMed Web of Science ®Google Scholar
• Allison BA, Pritchard PH, Richter AM, The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem Photobiol 1990;52:501-7
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Hasan T, Schomacker K, In vivo uptake of liposomal benzoporphyrin derivative and photothrombosis in experimental corneal neovascularization. Lasers Surg Med 1995;17(2):178-88
   PubMed Web of Science ®Google Scholar
• Richter AM, Yip S, Meadows H, Photosensitizing potencies of the structural analogues of benzoporphyrin derivative in different biological test systems. J Clin Laser Med Surg 1996;14(5):335-41
   PubMedGoogle Scholar
• Khanum F, Jain V. Cellular accumulation and biological activity of hematoporphyrin derivative (L) in comparison with photofrin II. Indian J Exp Biol 1997;35(4):348-55
   PubMedGoogle Scholar
• Miller JW, Schmidt-Erfurth U, Sickenberg M, Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related macular degeneration: results of a single treatment in a phase 1 and 2 study. Arch Ophthalmol 1999;117(9):1161-73
   PubMedGoogle Scholar
• Jamieson CH, McDonald WN, Levy JG. Preferential uptake of benzoporphyrin derivative by leukemic versus normal cells. Leuk Res 1990;14(3):209-19
   PubMed Web of Science ®Google Scholar
• Chowdhary RK, Shariff I, Dolphin D. Drug release characteristics of lipid based benzoporphyrin derivative. J Pharm Pharm Sci 2003;6(1):13-19
   PubMed Web of Science ®Google Scholar
• Polo L, Valduga G, Jori G, Reddi E. Low-density lipoprotein receptors in the uptake of tumour photosensitizers by human and rat transformed fibroblasts. Int J Biochem Cell Biol 2002;34(1):10-23
   PubMed Web of Science ®Google Scholar
• Haimovici R, Kramer M, Miller JW, Localization of lipoprotein-delivered benzoporphyrin derivative in the rabbit eye. Curr Eye Res 1997;16(2):83-90
   PubMed Web of Science ®Google Scholar
• Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials TAP report. Arch Ophthalmol 1999;117(10):1329-45
   PubMed Web of Science ®Google Scholar
• Bressler NM; Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials – TAP report 2. Arch Ophthalmol 2001;119(2):198-207
   PubMed Web of Science ®Google Scholar
• verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial – VIP report no. 1. Ophthalmology 2001;108:841-52
   PubMed Web of Science ®Google Scholar
• Blinder KJ, Blumenkranz MS, Bressler NM, verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial – VIP report no. 3. Ophthalmology 2003;110:667-73
   PubMed Web of Science ®Google Scholar
• Bandello F, Blinder K, Bressler NM, verteporfin in Photodynamic Therapy: report no. 5. Ophthalmology 2004;111:2144
   PubMed Web of Science ®Google Scholar
• Kaiser PK; VIO study group. verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. Curr Med Res Opin 2009;25(8):1853-60
   PubMed Web of Science ®Google Scholar
• Harding SP, Tomlin K. Reeves BC, et al. verteporfin Photodynamic Therapy Cohort Study: report 1: Effectiveness and Factors Influencing Outcomes. Ophthalmology 2009;116:e1-8
   PubMedGoogle Scholar
• Boyer DS, Antoszyk AN, Awh CC, MARINA Study Group. Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(2):246-52
   PubMed Web of Science ®Google Scholar
• Gharbiya M, Giustolisi R, Allievi F, Choroidal neovascularization in pathologic myopia: intravitreal ranibizumab versus bevacizumab–a randomized controlled trial. Am J Ophthalmol 2010;149(3):458-64
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Blodi BA, Shapiro H, Acharya NR; MARINA Study Group. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007;114(10):1868-75
   PubMed Web of Science ®Google Scholar
• Keane PA, Heussen FM, Ouyang Y, Assessment of Differential Pharmacodynamic Effects using Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration. Invest Ophthalmol Vis Sci 2012;53(3):1152-61
   PubMed Web of Science ®Google Scholar
• Irigoyen C, Ziahosseini K, Morphis G, Endophthalmitis following intravitreal injections. Graefes Arch Clin Exp Ophthalmol 2011;250(4):499-505
   PubMed Web of Science ®Google Scholar
• Lim LS, Cheung CM, Mitchell P, Wong TY. Emerging evidence concerning systemic safety of anti-VEGF agents–should ophthalmologists be concerned? Am J Ophthalmol 2011;152(3):329-31
   PubMed Web of Science ®Google Scholar
• Debefve E, Cheng C, Schaefer SC, Photodynamic therapy induces selective extravasation of macromolecules: insights using intravital microscopy. J Photochem Photobiol B 2010;98(1):69-76
   PubMed Web of Science ®Google Scholar
• Ishikawa K, Nishihara H, Ozawa S, Focal macular electroretinograms after photodynamic therapy combined with intravitreal bevacizumab. Graefes Arch Clin Exp Ophthalmol 2011;249(2):273-80
   PubMed Web of Science ®Google Scholar
• Potter MJ, Claudio CC, Szabo SM. A randomised trial of bevacizumab and reduced light dose photodynamic therapy in age-related macular degeneration: the VIA study. Br J Ophthalmol 2010;94(2):174-9
   PubMed Web of Science ®Google Scholar
• Rudnisky CJ, Liu C, Ng M, Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up. Retina 2010;30:548-54
   PubMed Web of Science ®Google Scholar
• Vallance JH, Johnson B, Majid MA, A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. Eye (Lond) 2010;24(10):1561-7
   PubMed Web of Science ®Google Scholar
• Jyothi S, Chowdhury HR, Chong V, Sivaprasad S. Anti-VEGF therapy for choroidal neovascularisation previously treated with photodynamic therapy. Eye 2010;24:1018-23
   PubMed Web of Science ®Google Scholar
• Kaiser PK, Boyer DS, Cruess AF, verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study. Retina 2012;119(5):1001-10
   Google Scholar
• Larsen M, Schmidt-Erfurth U, Lanzette P, verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study. Retina 2012;119(5):992-1000
   Google Scholar
• Ciardella AP, Donsoff IM, Huang SJ, Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004;49(1):25-37
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Tano Y, Photodynamic therapy in macular diseases of asian populations: when East meets West. Jpn J Ophthalmol 2006;50(2):161-9
   PubMed Web of Science ®Google Scholar
• Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am J Ophthalmol 2009;148(1):70-8
   PubMed Web of Science ®Google Scholar
• Stangos AN, Gandhi JS, Nair-Sahni J, Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab. Am J Ophthalmol 2010;150(5):666-73
   PubMed Web of Science ®Google Scholar
• Otani A, Sasahara M, Yodoi Y, Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007;144(1):7-14
   PubMed Web of Science ®Google Scholar
• Uyama M, Wada M, Nagai Y, Polypoidal choroidal vasculopathy: natural history. Am J Ophthalmol 2002;133:639-48
   PubMed Web of Science ®Google Scholar
• Oishi A, Mandai M, Kimakura M, Characteristics of fine vascular network pattern associated with recurrence of polypoidal choroidal vasculopathy. Eye 2011;25(8):1020-6
   PubMed Web of Science ®Google Scholar
• Gomi F, Sawa M, Sakaguchi H, Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008;92(1):70-3
   PubMed Web of Science ®Google Scholar
• Kokame GT, Yeung L, Lai JC. Continuous anti-VEGF treatment with ranibizumab for polypoidal choroidal vasculopathy: an interim 6-month report. Br J Ophthalmol 2010;94(3):297-301
   PubMed Web of Science ®Google Scholar
• Chan WM, Lam DS, Lai TY, Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004;111(8):1576-84
   PubMed Web of Science ®Google Scholar
• Eandi CM, Ober MD, Freund KB, Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. Retina 2007;27(7):825-31
   PubMed Web of Science ®Google Scholar
• Koh A, Lee WK, Chen LJ, Everest study: Efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in Patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; E-Pub
   Web of Science ®Google Scholar
• Tomita K, Tsujikawa A, Yamashiro K, Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 2012;153(1):68-80
   PubMed Web of Science ®Google Scholar
• Yamashiro K, Tsujikawa A, Nishida A, Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy. Jpn J Ophthalmol 2008;52:457-62
   PubMed Web of Science ®Google Scholar
• Akaza E, Yuzawa M, Mori R. Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011;55(1):39-44
   PubMed Web of Science ®Google Scholar
• Tsuchiya D, Yamamoto T, Kawasaki R, Yamashita H. Two year visual outcomes after photodynamic therapy in age-related macular degeneration patients with or without polypoidal choroidal vasculopathy lesions. Retina 2009;29:960-5
   PubMed Web of Science ®Google Scholar
• Sagong M, Lim S, Chang W. Reduced-Fluence Photodynamic Therapy Combined With Intravitreal Bevacizumab for Polypoidal Choroidal Vasculopathy. Am J Ophthalmol 2012;153(5):873-82
   PubMed Web of Science ®Google Scholar
• Machida S, Nishimura T, Tamada K, Macular function evaluated by focal macular electroretinograms after reduced fluence photodynamic therapy in eyes with polypoidal choroidal vasculopathy. Doc Ophthalmol 2011;124(2):91-8
   PubMed Web of Science ®Google Scholar
• Chan MC, Lim TH, Pece A, Silva R. Yoshimura N. verteporfin PDT for non-standard indications—a review of current literature. Graefes Arch Clin Exp Ophthalmol 2010;248:613-26
   PubMed Web of Science ®Google Scholar
• Imasawa M, Sakurada Y, Iijima H. Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy. Jpn J Ophthalmol 2011;55(3):241-7
   PubMed Web of Science ®Google Scholar
• Barbazetto I, Schmidt-Erfurth U. Photodynamic therapy of choroidal hemangioma: two case reports. Graefes Arch Clin Exp Ophthalmol 2000;238(3):214-21
   PubMed Web of Science ®Google Scholar
• Gambrelle J, Graswill C, Mauget-Faysse M, Treatment of circumscribed choroidal haemangiomas by photodynamic therapy: a review. J Fr Ophtalmol 2010;33(7):497-504
   PubMed Web of Science ®Google Scholar
• Blasi MA, Tiberti AC, Scupola A, Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes. Ophthalmology 2010;117(8):1630-7
   PubMed Web of Science ®Google Scholar
• Landau IM, Steen B, Seregard S. Photodynamic therapy for circumscribed choroidal haemangioma. Acta Ophthalmol Scand 2002;80(5):531-6
   PubMedGoogle Scholar
• Madreperla SA.. Choroidal hemangioma treated with photodynamic therapy using verteporfin. Arch Ophthalmol 2001;119:1606-10
   PubMed Web of Science ®Google Scholar
• Gupta M, Singh AD, Rundle PA, Rennie IG. Efficacy of photodynamic therapy in circumscribed choroidal haemangioma. Eye (Lond) 2004;18(2):139-42
   PubMed Web of Science ®Google Scholar
• Soucek P, Cihelkova I. Evaluation of subretinal fluid absorption by optical coherence tomography in circumscribed choroidal hemangioma after photodynamic therapy with verteporfin. Neuro Endocrinol Lett 2004;25(1-2):109-14
   PubMed Web of Science ®Google Scholar
• Verbraak FD, Schlingemann RO, de Smet MD, Keunen JE. Single spot PDT in patients with circumscribed choroidal haemangioma and near normal visual acuity. Graefes Arch Clin Exp Ophthalmol 2006;244(9):1178-82
   PubMed Web of Science ®Google Scholar
• Michels S, Michels R, Simader C. Schmidt-Erfurth U. verteporfin therapy for choroidal hemangioma: a long-term follow-up. Retina 2005;25(6):697-703
   PubMed Web of Science ®Google Scholar
• Jurklies B, Anastassiou G, Ortmans S, Photodynamic therapy using verteporfin in circumscribed choroidal haemangioma. Br J Ophthalmol 2003;87(1):84-9
   PubMed Web of Science ®Google Scholar
• Pilotto E, Urban F, Parrozzani R, Midena E. Standard versus bolus photodynamic therapy in circumscribed choroidal hemangioma: functional outcomes. Eur J Ophthalmol 2011;21(4):452-8
   PubMed Web of Science ®Google Scholar
• Gambrelle J, Graswill C, Mauget-Faysse M, Treatment of circumscribed choroidal haemangiomas by photodynamic therapy: a review. J Fr Ophtalmol 2010;33(7):497-504
   PubMed Web of Science ®Google Scholar
• Porrini G, Giovannini A, Amato G, Photodynamic therapy of circumscribed choroidal hemangioma. Ophthalmology 2003;110(4):674-80
   PubMed Web of Science ®Google Scholar
• Elizalde J, Vasquez L, Iyo F, Abengoechea S. Photodynamic therapy in the management of circumscribed choroidal hemangioma. Can J Ophthalmol 2012;47(1):16-20
   PubMed Web of Science ®Google Scholar
• Tsipursky MS, Golchet PR, Jampol LM. Photodynamic therapy of choroidal hemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. Surv Ophthalmol 2011;56(1):68-85
   PubMed Web of Science ®Google Scholar
• Boixadera A, Garcia-Arumi J, Martinez-Castillo V, Prospective clinical trial evaluating the efficacy of photodynamic therapy for symptomatic circumscribed choroidal hemangioma. Ophthalmology 2009;116(1):100-5. e1
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Spyridaki M, Stroux A, Therapy for peripapillary located and large choroidal haemangioma with PDT ‘paint-brush technique'. Klin Monbl Augenheilkd 2009;226(11):933-8
   PubMed Web of Science ®Google Scholar
• Tsipursky MS, Golchet PR, Jampol LM. Photodynamic therapy of choroidal hemangioma in sturge-weber syndrome, with a review of treatments for diffuse and circumscribed choroidal hemangiomas. Surv Ophthalmol 2011;56(1):68-85
   PubMed Web of Science ®Google Scholar
• Heimann H, Bornfeld N, Vij O, Vasoproliferative tumours of the retina. Br J Ophthalmol 2000;84(10):1162-9
   PubMed Web of Science ®Google Scholar
• Shields CL, Shields JA, Barrett J, De Potter P. Vasoproliferative tumors of the ocular fundus. Classification and clinical manifestations in 103 patients. Arch Ophthalmol 1995;113(5):615-23
   PubMedGoogle Scholar
• Rennie IG.. Retinal vasoproliferative tumors. Eye 2010;24:468-71
   PubMed Web of Science ®Google Scholar
• Rodriguez-Coleman H, Spaide RF, Yannuzzi LA. Treatment of angiomatous lesions of the retina with photodynamic therapy. Retina 2002;22:228-32
   PubMed Web of Science ®Google Scholar
• Barbezetto IA, Smith RT. Vasoproliferative tumor of the retima treated with PDT. Retina 2003;23(4):565-7
   PubMed Web of Science ®Google Scholar
• Blasi MA, Scupola A, Tiberti AC, Photodynamic therapy for vasoproliferative retinal tumors. Retina 2006;26(4):404-9
   PubMed Web of Science ®Google Scholar
• Osman S, Aylin Y, Arikan G, Photodynamic treatment of a secondary vasoproliferative tumour associated with sector retinitis pigmentosa and Usher syndrome type I. Clin Experiment Ophthalmol 2007;35:191-3
   PubMed Web of Science ®Google Scholar
• Saldanha MJ, Edrich C. Treatment of vasoproliferative tumors with photodynamic therapy. Ophthalmic Surg Lasers Imaging 2008;39:143-5
   PubMed Web of Science ®Google Scholar
• Chan RP, Lai TY. Photodynamic therapy with verteporfin for vasoproliferative tumour of the retina. Acta Ophthalmol 2010;88(6):711-12
   PubMed Web of Science ®Google Scholar
• Wong WT, Chew EY. Ocular von Hippel-Lindau disease: clinical update and emerging treatments. Curr Opin Ophthalmol 2008;19(3):213-17
   PubMed Web of Science ®Google Scholar
• Atebara NH.. Retinal capillary hemangioma treated with verteporfin photodynamic therapy. Am J Ophthalmol 2002;134(5):788-90
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth UM, Kusserow C, Barbazetto IA, Laqua H. Benefits and complications of photodynamic therapy of papillary capillary hemangiomas. Ophthalmology 2002;109(7):1256-66
   PubMed Web of Science ®Google Scholar
• Mennel S, Barbazetto I, Meyer CH, Ocular photodynamic therapy–standard applications and new indications. Part 2. Review of the literature and personal experience. Ophthalmologica 2007;221(5):282-91
   PubMed Web of Science ®Google Scholar
• Sachdeva R, Dadgostar H, Kaiser PK, verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. Acta Ophthalmol 2010;88(8):e334-40
   PubMed Web of Science ®Google Scholar
• Cheung J, Lee GK, Tham CC. A large retinal capillary hemangioma in the anterior retina treated with photodynamic therapy. Case Report Ophthalmol 2012;3(1):1-4
   Google Scholar
• Wong YM, Jalil A, Mathews J, Stanga PE. Exudative retinal detachment following photodynamic therapy for retinal capillary hemangioma. Can J Ophthalmol 2010;45(3):299-300
   PubMed Web of Science ®Google Scholar
• Baba T, Kitahashi M, Kubota-Taniai M, Subretinal hemorrhage after photodynamic therapy for juxtapapillary retinal capillary hemangioma. Case Report Ophthalmol 2011;2(1):134-9
   PubMedGoogle Scholar
• Ach T, Thiemeyer D, Hoeh AE, Intravitreal bevacizumab for retinal capillary haemangioma: longterm results. Acta Ophthalmol 2010;88(4):e137-8
   PubMed Web of Science ®Google Scholar
• von Buelow M, Pape S, Hoerauf H. Systemic bevacizumab treatment of a juxtapapillary retinal haemangioma. Acta Ophthalmol Scand 2007;85(1):114-16
   PubMedGoogle Scholar
• Ziemssen F, Voelker M, Inhoffen W, Combined treatment of a juxtapapillary retinal capillary haemangioma with intravitreal bevacizumab and photodynamic therapy. Eye (Lond) 2007;21(8):1125-6
   PubMed Web of Science ®Google Scholar
• Mennel S, Meyer CH, Callizo J. Combined intravitreal anti-vascular endothelial growth factor (Avastin) and photodynamic therapy to treat retinal juxtapapillary capillary haemangioma. Acta Ophthalmol 2010;88(5):610-13
   PubMed Web of Science ®Google Scholar
• Fong AH, Li KK, Wong D. Intravitreal ranibizumab, photodynamic therapy, and vitreous surgery for the treatment of juxtapapillary retinal capillary hemangioma. Graefes Arch Clin Exp Ophthalmol 2011;249(4):625-7
   PubMed Web of Science ®Google Scholar
• Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. Ophthalmology 2011;118(9):1881-5
   PubMed Web of Science ®Google Scholar
• Damato BE. Treatment selection for uveal melanoma. Dev Ophthalmol 2012;49:16-26
   PubMedGoogle Scholar
• Damato B, Eleuteri A, Taktak AF, Coupland SE. Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 2011;30(5):285-95
   PubMed Web of Science ®Google Scholar
• Sery TW, Shields JA, Augsburger JJ, Photodynamic therapy of human ocular cancer. Ophthalmic Surg 1987;18:413-18
   PubMedGoogle Scholar
• Kim RY, Hu LK, Foster BS, Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness. Ophthalmology 1996;103:2029-36
   PubMed Web of Science ®Google Scholar
• Young LH, Howard MA, Hu LK, Photodynamic therapy of pigmented choroidal melanomas using a liposomal preparation of benzoporphyrin derivative. Arch Ophthalmol 1996;114:186-92
   PubMed Web of Science ®Google Scholar
• Barbazetto IA, Lee TC, Rollins IS, Treatment of choroidal melanoma using photodynamic therapy. Am J Ophthalmol 2003;135:898-9
   PubMed Web of Science ®Google Scholar
• Favilla I, Favilla ML, Gosbell AD, Photodynamic therapy: a 5-year study of its effectiveness in the treatment of posterior uveal melanoma, and evaluation of haematoporphyrin uptake and photocytotoxicity of melanoma cells in tissue culture. Melanoma Res 1995;5(5):355-64
   PubMed Web of Science ®Google Scholar
• Lewis RA, Tse DT, Phelps CD, Weingeist TA. Neovascular glaucoma after photoradiation therapy for uveal melanoma. Arch Ophthalmol 1984;102(6):839-42
   PubMed Web of Science ®Google Scholar
• Wachtlin J, Bechrakis NE, Foerster MH. Photodynamic therapy with verteporfin for uveal melanoma. Ophthalmologe 2005;102(3):241-6
   PubMed Web of Science ®Google Scholar
• Sharma KV, Bowers N, Davids LM. Photodynamic therapy-induced killing is enhanced in depigmented metastatic melanoma cells. Cell Biol Int 2011;35(9):939-44
   PubMed Web of Science ®Google Scholar
• Campbell WG, Pejnovic TM. Tretament of amelanotic choroidal melanoma with photodynamic therapy. Retina 2011; E-Pub
   Web of Science ®Google Scholar
• Garcia-Arumi J, Amselem L, Gunduz K, Photodynamic therapy for symptomatic subretinal fluid related to choroidal nevus. Retina 2012;32(5):936-41
   PubMed Web of Science ®Google Scholar
• Blom DJ, Schuitmaker HJ, de Waard-Siebinga I, Decreased expression of HLA class I on ocular melanoma cells following in vitro photodynamic therapy. Cancer Lett 1997;112(2):239-43
   PubMed Web of Science ®Google Scholar
• Pryds A, Larsen M. Choroidal thickness following extrafoveal photodynamic treatment with verteporfin in patients with central serous chorioretinopathy. Acta Ophthalmol 2011; E-Pub
   PubMed Web of Science ®Google Scholar
• Maruko I, Iida T, Sugano Y, Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010;117(9):1792-9
   PubMed Web of Science ®Google Scholar
• Spaide RF, Hall L, Haas A, Indocyanine green videoangiography of older patients with central serous chorioretinopathy. Retina 1996;16:203-13
   PubMed Web of Science ®Google Scholar
• Wang M, Munch IC, Hasler PW, Central serous chorioretinopathy. Acta Ophthalmol 2008;86:126-45
   PubMed Web of Science ®Google Scholar
• Bandello F, Virgili G, Lanzetta P, ICG angiography and retinal pigment epithelial decompensation (CRSC and epitheliopathy). J Fr Ophtalmol 2001;24:448-51
   PubMed Web of Science ®Google Scholar
• Yannuzzi LA.. Central serous chorioretinopathy: a personal perspective. Am J Ophthalmol 2010;149(3):361-3
   PubMed Web of Science ®Google Scholar
• Inoue R, Sawa M, Tsujikawa M, Gomi F. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. Am J Ophthalmol 2010;149(3):441-6. e1-2
   PubMed Web of Science ®Google Scholar
• Wang M, Munch IC, Hasler PW, Central serous chorioretinopathy. Acta Ophthalmol 2008;86(2):126-45
   PubMed Web of Science ®Google Scholar
• Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010;24(12):1743-56
   PubMed Web of Science ®Google Scholar
• Ross A, Ross AH, Mohamed Q. Review and update of central serous chorioretinopathy. Curr Opin Ophthalmol 2011;22(3):166-73
   PubMed Web of Science ®Google Scholar
• Moon JW, Yu HG, Kim TW, Prognostic factors related to photodynamic therapy for central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol 2009;247:1315-23
   PubMed Web of Science ®Google Scholar
• Ober MD, Yannuzzi LA, Do DV, Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy. Ophthalmology 2005;112:2088-94
   PubMed Web of Science ®Google Scholar
• Tarantola RM, Law JC, Recchia FM, Photodynamic therapy as treatment of chronic idiopathic central serous chorioretinopathy. Lasers Surg Med 2008;40:671-5
   PubMed Web of Science ®Google Scholar
• Ozmert E, Batioglu F. Fundus autofluorescence before and after photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmologica 2009;223:263-8
   PubMed Web of Science ®Google Scholar
• Lee PY, Kim KS, Lee WK. Severe choroidal ischemia following photodynamic therapy for pigment epithelial detachment and chronic central serous chorioretinopathy. Jpn J Ophthalmol 2009;53(1):52-6
   PubMed Web of Science ®Google Scholar
• Lai TY, Chan WM, Li H, Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study. Br J Ophthalmol 2006;90(7):869-74
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Lai RY, Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008;28(1):85-93
   PubMed Web of Science ®Google Scholar
• Chan WM, Lai TY, Lai RY, Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology 2008;115(10):1756-65
   PubMed Web of Science ®Google Scholar
• Zhao MW, Zhou P, Xiao HX, Photodynamic therapy for acute central serous chorioretinopathy: the safe effective lowest dose of verteporfin. Retina 2009;29(8):1155-61
   PubMed Web of Science ®Google Scholar
• Reibaldi M, Cardascia N, Longo A, Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. Am J Ophthalmol 2010;149(2):307-15
   PubMed Web of Science ®Google Scholar
• Bae SH, Heo JW, Kim C, A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy. Am J Ophthalmol 2011;152(5):784-92
   PubMed Web of Science ®Google Scholar
• Reibaldi M, Boscia F, Avitabile T, Functional retinal changes measured by microperimetry in standard-fluence vs low-fluence photodynamic therapy in chronic central serous chorioretinopathy. Am J Ophthalmol 2011;151(6):953-60
   PubMed Web of Science ®Google Scholar
• Senturk F, Karacorlu M, Ozdemir H, Microperimetric changes after photodynamic therapy for central serous chorioretinopathy. Am J Ophthalmol 2011;151(2):303-9
   PubMed Web of Science ®Google Scholar
• Kim SW, Oh J, Oh IK, Huh K. Retinal pigment epithelial tear after half fluence PDT for serous pigment epithelial detachment in central serous chorioretinopathy. Ophthalmic Surg Lasers Imaging 2009;40(3):300-3
   PubMed Web of Science ®Google Scholar
• Chan CK, Abraham P, Meyer CH, Optical coherence tomography-measured pigment epithelial detachment height as a predictor for retinal pigment epithelial tears associated with intravitreal bevacizumab injections. Retina 2010;30(2):203-11
   PubMed Web of Science ®Google Scholar
• Michels S, Hansmann F, Geitzenauer W, Schmidt-Erfurth U. Influence of treatment parameters on selectivity of verteporfin therapy. Invest Ophthalmol Vis Sci 2006;47(1):371-6
   PubMed Web of Science ®Google Scholar
• Sandell JL, Zhu TC. A review of in-vivo optical properties of human tissues and its impact on PDT. J Biophotonics 2011;4(11-12):773-87
   PubMed Web of Science ®Google Scholar
• Framme C, Flucke B, Birngruber R. Comparison of reduced and standard light application in photodynamic therapy of the eye in two rabbit models. Graefes Arch Clin Exp Ophthalmol 2006;244(7):773-81
   PubMed Web of Science ®Google Scholar
• Schlotzer-Schrehardt U, Viestenz A, Naumann GO, Dose-related structural effects of photodynamic therapy on choroidal and retinal structures of human eyes. Graefes Arch Clin Exp Ophthalmol 2002;240(9):748-57
   PubMed Web of Science ®Google Scholar
• Henderson BW, Busch TM, Snyder JW. Fluence rate as a modulator of PDT mechanisms. Lasers Surg Med 2006;38(5):489-93
   PubMed Web of Science ®Google Scholar
• Busch TM, Wang HW, Wileyto EP, Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate. Radiat Res 2010;174(3):331-40
   PubMed Web of Science ®Google Scholar
• Naghavi N, Miranbaygi MH, Sazgarnia A. Simulation of fractionated and continuous irradiation in photodynamic therapy: study the differences between photobleaching and singlet oxygen dose deposition. Australas Phys Eng Sci Med 2011;34(2):203-11
   PubMed Web of Science ®Google Scholar
• Middelburg TA, Van Zaane F, De Bruijn HS, Fractionated illumination at low fluence rate photodynamic therapy in mice. Photochem Photobiol 2010;86(5):1140-6
   PubMed Web of Science ®Google Scholar
• Wang KK, Mitra S, Foster TH. A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy. Med Phys 2007;34(1):282-93
   PubMed Web of Science ®Google Scholar
• Wang KK, Finlay JC, Busch TM, Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modeling. J Biophotonics 2010;3(5-6):304-18
   PubMed Web of Science ®Google Scholar
• Jarvi MT, Patterson MS, Wilson BC. Insights into photodynamic therapy dosimetry: simultaneous singlet oxygen luminescence and photosensitizer photobleaching measurements. Biophys J 2012;102(3):661-71
   PubMed Web of Science ®Google Scholar
• Aquaron R, Forzano O, Murati JL, Simple, reliable and fast spectrofluorometric method for determination of plasma verteporfin (Visudyne) levels during photodynamic therapy for choroidal neovascularization. Cell Mol Biol (Noisy-le-grand) 2002;48(8):925-30
   PubMed Web of Science ®Google Scholar
• Samkoe KS, Clancy AA, Karotki A, Complete blood vessel occlusion in the chick chorioallantoic membrane using two-photon excitation photodynamic therapy: implications for treatment of wet age-related macular degeneration. J Biomed Opt 2007;12(3):034025
   PubMed Web of Science ®Google Scholar
• Mayo GL, Melendez RF, Kumar N, Antibody-targeted photodynamic therapy. Am J Ophthalmol 2003;136(6):1151-2
   PubMed Web of Science ®Google Scholar
• Lu F, Hu Z, Sinard J, Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. Invest Ophthalmol Vis Sci 2009;50(8):3890-6
   PubMed Web of Science ®Google Scholar
• Schmitt F, Juillerat-Jeanneret L. Drug Targeting Strategies for Photodynamic Therapy. Anticancer Agents Med Chem 2012;12(5):500-25
   PubMed Web of Science ®Google Scholar
• Mozaffarieh M, Schotzau A, Josifova T, Flammer J. The effect of ranibizumab versus photodynamic therapy on DNA damage in patients with exudative macular degeneration. Mol Vis 2009;15:1194-9
   PubMed Web of Science ®Google Scholar
• Firczuk M, Nowis D, Gołab J. PDT-induced inflammatory and host responses. Photochem Photobiol Sci 2011;10(5):653-63
   PubMed Web of Science ®Google Scholar
• Rodrigues M, Meira D, Batista S, Carrilho MM. Accidental pregnancy exposure to verteporfin: obstetrical and neonatal outcomes: a case report. Aust N Z J Obstet Gynaecol 2009;49(2):236-7
   PubMed Web of Science ®Google Scholar
• Jalil A, Mercieca K, Chaudhry NL, Choroidal nonperfusion with significant subretinal exudation after PDT of predominantly classic CNV: an OCT and FFA study. Eur J Ophthalmol 2009;19:490-3
   PubMed Web of Science ®Google Scholar
• Schmidt-Erfurth U, Kiss C, Sacu S. The role of choroidal hypoperfusion associated with photodynamic therapy in neovascular age-related macular degeneration and the consequences for combination strategies. Prog Retin Eye Res 2009;28(2):145-54
   PubMed Web of Science ®Google Scholar
• Moon JW, Kim YJ, Khwarg SI, Chorioretinal ischemia and angiogenic milieu following photodynamic therapy. Curr Eye Res 2010;35(4):314-21
   PubMed Web of Science ®Google Scholar
• Tsuchihashi T, Mori K, Peyman G, Photodynamic effects on retinal oxygen saturation, blood flow, and electrophysiological function in patients with neovascular age-related macular degeneration. Retina 2009;29(10):1450-6
   PubMed Web of Science ®Google Scholar
• Vinh Moreau-Gaudry V, Geiser M, Romanet JP, Effects of photodynamic therapy on subfoveal blood flow in neovascular age-related macular degeneration patients. Eye (Lond) 2010;24(4):706-12
   PubMed Web of Science ®Google Scholar
• Turkuoglu P, Ozturkmen C, Ilhan N, Retinal nitric oxide and malonyldialdehyde levels following photodynamic therapy. Indian J Ophthalmol 2011;59(1):5-8
   PubMed Web of Science ®Google Scholar
• Fujita K, Yuzawa M, Mori R. Retinal sensitivity after photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy: short-term results. Retina 2011;31(4):772-8
   PubMed Web of Science ®Google Scholar